Skip to content
Low Dose GLP-1Providers

Evidence review

How Many Units Is a Microdose in an Ozempic or Wegovy Pen?

How many clicks or units make a GLP-1 microdose? An Ozempic pen chart from the label, the folk click math, and why Novo Nordisk says not to count clicks.

Updated Lena Ortiz

On this page

Featured partner

CoreAge Rx

$149–$199/mo microdose ($99–$149 standard)

Two named microdosing programs with their own monthly prices, sold beside standard plans that cost less.

Check availability
Category
Telehealth · GLP-1 microdose
Pricing
Flat monthly price
Support
Clinician review included
Labs
No labs required

Advertising disclosure · an affiliate partner. We may earn a commission at no extra cost to you.

Partner

RxSpan MD

All-inclusive compounded GLP-1 pricing for injections and oral capsules, with a month-to-month plan and brand-name pens priced up front.

$249/mo month to month ($199 on 6-mo)

Check RxSpan MD availability

One of the most common questions in microdosing forums is mechanical, not medical: how many clicks, or how many units, is a "microdose" in an Ozempic or Wegovy pen? People reach for this question because a branded pen is expensive and they want to stretch it, or because they want a dose below the lowest step on the official ladder. This page answers the math honestly — but the honest answer comes with a warning that the marketing around microdosing tends to bury: the way these pens are built, click-counting to hit a custom sub-dose is exactly what the manufacturer designed against, and it is an easy way to dose yourself wrong.

So we'll do two things. We'll explain how the pens actually deliver dose — and why "18 clicks ≈ 0.25 mg" is a rough folk-conversion, not a manufacturer instruction. And we'll be clear that if your real goal is a controlled low dose, a compounded vial measured in true units is a more honest tool than improvising on a fixed-dose pen — with its own caveats, which we cover in how to reconstitute and measure a compounded GLP-1 microdose.

First, the honest framing: there is no approved "microdose"

Before any math: no GLP-1 manufacturer makes a microdose, and no trial has tested intentional microdosing. The Wegovy and Ozempic labels define a fixed ladder of approved doses, and the lowest rung — 0.25 mg once weekly for semaglutide — is a starter dose meant to build tolerance on the way up, not a maintenance dose proven to do much on its own 1. A "microdose" sits below even that starter step, in territory no label and no randomized trial covers 2. Everything below is about the mechanics of the device, not an endorsement that a sub-starter dose works.

Where a microdose sits

Microdose

Below 0.25 mg — no label, no trial

0.25 mg / week

Starter step, builds tolerance

2.4 mg / week

Full dose — where evidence comes from

A microdose is below the lowest rung any label or trial covers. Source: Wegovy FDA prescribing information; STEP-trial dose ladder.

How the pens actually deliver a dose

This is where Ozempic and Wegovy differ, and the difference matters for anyone counting clicks.

The Ozempic pen is a multi-dose, dial-a-dose device. A single Ozempic pen is designed to deliver several fixed doses from one cartridge — you dial the dose, and the pen meters it out. The pen audibly clicks as it dials, which is the origin of the "count the clicks" folklore. The Ozempic label specifies the discrete doses the pen is built to give (for example 0.25 mg and 0.5 mg from the lower-strength pen) and instructs the user to dial to the marked dose, not to an arbitrary point between marks 3.

Wegovy pens leave even less room. Most Wegovy pens are single-dose, fixed-dose injectors: one pen, one pre-set dose, no dial, from 0.25 mg up to the 7.2 mg Wegovy HD pen. There is nothing to "count" — you press and the full pre-set dose goes in. The newer Wegovy FlexTouch pen does have a dial and holds four weekly doses, but the only dose it can select is 2.4 mg, and its instructions also say not to set the dose by counting clicks 1. Neither design makes Wegovy something you can microdose without physically defeating the device, which is not a thing the label contemplates or supports.

So the "how many units is a microdose" question is really an Ozempic-pen question, dressed up.

Tirzepatide answers it differently again, and worse: Mounjaro and Zepbound each ship in four presentations at two different volumes per dose, so the same milligram figure converts to a different number of units depending on which container you hold. That arithmetic is worked through in how many units is a microdose of tirzepatide?.

Ozempic pen clicks chart (2 mg, 4 mg and 8 mg pens)

Novo Nordisk does not publish a clicks chart. The Ozempic instructions say it in as many words: "Do not count the pen clicks." What the label does publish is what each pen holds and which doses it can dial 3:

Pen (total semaglutide)VolumeStrengthDoses it can dialDoses per pen
2 mg pen3 mL0.68 mg/mL0.25 mg or 0.5 mg4 doses of 0.25 mg and 2 of 0.5 mg, or 4 doses of 0.5 mg
4 mg pen3 mL1.34 mg/mL1 mg4 doses of 1 mg
8 mg pen3 mL2.68 mg/mL2 mg4 doses of 2 mg

The dose counter on every one of these pens reads in milligrams, not clicks or units, and the label says the selected dose has to line up exactly with the dose pointer to be correct. The 8 mg pen is about four times as concentrated as the 2 mg pen, so a dose estimated by counting on one pen does not carry over to the other. Ozempic also comes in single-dose prefilled syringes of 0.25, 0.5 and 1 mg, which have no dial at all 3.

The click counts you see online come from people counting, not from Novo Nordisk. Our pen click estimator shows those community figures pen by pen, with the label's warning attached.

The folk math — and why it's only folk math

Here is the conversion people circulate, stated plainly so we can then knock it down. Ozempic's lowest-strength pen holds 2 mg of semaglutide in 3 mL and is built to give 0.25 mg or 0.5 mg doses 3. People who count clicks report that a full 0.25 mg dose corresponds to roughly 18–19 clicks on that pen — the same arithmetic our pen click estimator runs, with the manufacturer's "do not count the pen clicks" warning attached — so they reason that "half a click is half the drug" and dial a fraction to chase a microdose.

The arithmetic is internally consistent, but it rests on assumptions the manufacturer never validated:

  • The pen is not graduated for sub-doses. Its dose window shows the approved doses, not units. Stopping between marks means you are estimating, not measuring 3.
  • Click-to-dose linearity is assumed, not guaranteed. A consistent dose depends on a full, uninterrupted press to the stop; partial actuations can under-deliver unpredictably, and air or priming losses are not evenly distributed across "clicks."
  • It voids the one thing a fixed-dose pen is good at — accuracy. The entire reason a dial-a-dose pen exists is to remove guesswork; counting clicks to a custom number puts the guesswork back.

This is why the clinical literature that addresses microdosing treats pen manipulation as a safety hazard — flagging dosing errors and device misuse rather than offering a clicks-to-milligrams chart 2. We are giving you the folk math so you understand what people mean, not because it's a reliable way to dose a potent drug.

Pen by pen

Ozempic penWegovy penCompounded vial
TypeMulti-dose dial-a-doseSingle-dose fixed injector, or FlexTouch (4 doses of 2.4 mg)Vial + insulin syringe
Can you 'count units'?Clicks only — not graduated for sub-dosesSingle-dose: no dial. FlexTouch: dials 2.4 mg onlyYes — true volume in units
Microdose feasible?Only by defeating the designEffectively noYes, but measurement ≠ proven benefit
Main caveatClick-counting = dosing error riskFixed dose by designGray-market; prep/contamination risk
Neither branded pen is designed for microdosing. Sources: Ozempic and Wegovy FDA labels; compounded-GLP-1 pharmacovigilance analysis.

Why a compounded vial is the more honest low-dose tool

If your actual goal is a deliberately low, measured dose, the device built for that is a vial and a syringe — not a fixed-dose pen you're fighting against. With a compounded vial of known concentration (say, milligrams per milliliter), you draw a true volume in insulin-syringe units, and the dose is something you can calculate and repeat rather than estimate by ear. That's why most people who microdose in practice use compounded product, not a manipulated brand pen 2.

But "more honest tool" is not "safe and proven." Compounded GLP-1s are not FDA-approved finished drugs, and a pharmacovigilance analysis of compounded GLP-1 agonists found markedly elevated reporting odds for preparation errors (reporting odds ratio roughly 48.9), contamination (about 19.0), and compounding problems (about 8.5), alongside more reports of abdominal pain, gallbladder inflammation, and hospitalization 4. So the trade is real: a vial lets you measure a low dose accurately, but it shifts you onto a gray-market product with its own documented risks. We dig into that in is compounded / microdosed GLP-1 safe? and walk through legitimate access routes in how to get microdosing tirzepatide.

What even a correctly measured low dose can — and can't — promise

Suppose you nail the measurement. The deeper problem remains: a sub-therapeutic dose is, by definition, below where the benefits were demonstrated. Semaglutide works by mimicking the gut hormone GLP-1 — slowing gastric emptying, suppressing glucagon, and acting on appetite centers in the brain — and those effects depend on enough drug being present to occupy enough receptors 5. Dose-finding data show weight loss shrinking steadily as the dose falls: in a phase 2 dose-ranging trial, semaglutide produced about 6% weight loss at 0.05 mg versus roughly 14% at the top dose tested 6, and the headline STEP 1 result (about 14.9% mean loss) came from the full 2.4 mg dose 7. A microdose sits below even the lowest dose in that trial. Getting the units right doesn't change the dose-response reality, which we cover in GLP-1 dose-response: why lower doses do less.

The bottom line on clicks and units

The clicks-to-milligrams conversion people pass around (roughly 18 clicks per 0.25 mg on the low-strength Ozempic pen) exists, and we've explained it — but it's folklore layered on top of a device that was engineered specifically to prevent improvised dosing. Novo Nordisk discourages click-counting because a fixed-dose pen's whole value is accuracy, and counting clicks to a custom sub-dose throws that away and invites dosing error 23. Wegovy's single-dose pens can't be microdosed at all without defeating the device, and the Wegovy FlexTouch dials only 2.4 mg. If you genuinely want a controlled low dose, a compounded vial measured in real units is the more honest instrument — but it carries its own compounding and contamination risks 4, and no amount of careful measurement makes a sub-therapeutic dose match the benefits proven at the full dose 67. Talk to a qualified clinician before improvising with any GLP-1 device.

For the bigger picture, start with our pillar, microdosing GLP-1: what the evidence actually shows, and our deep dive on microdosing semaglutide. For a visual map of where doses sit, see our GLP-1 microdosing dose chart, and to compare providers, our GLP-1 microdose rankings hub.

Frequently asked

How many units is a microdose in an Ozempic pen?

There is no official answer, because the Ozempic pen is not graduated in units — it's a dial-a-dose device built to deliver fixed approved doses (like 0.25 mg and 0.5 mg). People circulate a folk conversion of roughly 18 clicks per 0.25 mg, but counting clicks to a custom sub-dose is unvalidated, defeats the pen's built-in accuracy, and is treated as a dosing-error hazard in the clinical literature. Novo Nordisk discourages it.

Can you microdose a Wegovy pen?

Effectively no. Most Wegovy pens are single-use, fixed-dose injectors with no dial — one pen delivers one pre-set dose. The multi-dose Wegovy FlexTouch has a dial, but the only dose it can select is 2.4 mg. Either way there is nothing to count down to a smaller dose, so a Wegovy pen can't be microdosed without physically defeating the device, which the label does not support.

Is a compounded vial better for microdosing than a brand pen?

It's a more honest measuring tool, because a vial of known concentration lets you draw a true low dose in insulin-syringe units rather than guessing between pen clicks. But it's not safer overall: compounded GLP-1s are not FDA-approved, and pharmacovigilance data show elevated reports of preparation errors, contamination, and compounding problems. Measuring accurately doesn't make a sub-therapeutic dose match full-dose benefits.

Why does the manufacturer discourage click-counting?

Because a fixed-dose pen's entire value is accuracy. It's engineered to deliver a precise, repeatable dose with a full press to the stop. Counting clicks to land on a custom number between the marked doses reintroduces the exact guesswork the device was designed to remove, and partial actuations can under-deliver unpredictably.

References

  1. Novo Nordisk (manufacturer label) (2026). WEGOVY (semaglutide) injection — FDA prescribing information (Dosage and Administration; Dosage Forms and Strengths: single-dose pens, Wegovy HD 7.2 mg, Wegovy FlexTouch; Instructions for Use). DailyMed (NIH/NLM), FDA label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  2. Trainer N, et al. (2026). The "microdosing" dilemma: Balancing patient anecdotes with clinical safety amid GLP-1 compounding restrictions. Journal of the American Association of Nurse Practitioners. https://pubmed.ncbi.nlm.nih.gov/42201545/
  3. Novo Nordisk (manufacturer label) (2026). OZEMPIC (semaglutide) injection — FDA prescribing information (Dosage Forms and Strengths; How Supplied: 2 mg, 4 mg and 8 mg pens and single-dose syringes; Instructions for Use). DailyMed (NIH/NLM), FDA label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
  4. McCall KL, et al. (2026). Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opinion on Drug Safety. https://pubmed.ncbi.nlm.nih.gov/40285721/
  5. Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metabolism. https://pubmed.ncbi.nlm.nih.gov/29617641/
  6. O'Neil PM, et al. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet. https://pubmed.ncbi.nlm.nih.gov/30122305/
  7. Wilding JPH, et al. (STEP 1) (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Continue reading